Main Conference Day 2Wednesday, 25 February 2026

We have developed a self-assembly technology utilizing hairpin DNA. The designed hairpin DNA self-assembles into long double-stranded DNA in the presence of cancer-associated miRNAs, functioning as a selective immune-amplification and booster circuit to induce the lysis of target tumors.

Immune-modulating nanobiologics (INBs) are a new class of lipid nanoparticle (LNP)-encapsulated therapeutic mRNAs, designed by integrating viral immune evasion strategies, insights into intracellular pathways driving pathological immune responses, and recent advances in mRNA-based therapeutics. This innovative approach offers a promising treatment modality for the treatment of autoimmune and autoinflammatory (I&I) diseases. Our studies on INB3 show that it was safe and demonstrated potent inhibition of type I interferon production and significant therapeutic benefit in a murine model of SLE, highlighting its potential as a novel treatment for the treatment of I&I diseases associated with aberrant type I IFNs expression. These preliminary findings warrant further investigation in advanced preclinical models to support the initiation of early-phase clinical trials as a targeted immunomodulatory therapy for SLE and other IFN-driven I&I diseases.

We developed BDDS, a polymer-based platform that targets LAT1 on brain endothelium to enable systemic oligonucleotide delivery across the blood–brain barrier. By presenting small LAT1-targeting ligands at high multivalent density, BDDS promotes cellular uptake and broad brain delivery. In chronic epilepsy models, a single intravenous dose of our anti-miR ASO formulation produced durable target engagement and sustained seizure protection. These preclinical findings support BDDS as a promising platform for non-invasive CNS RNA therapeutics and a potential alternative to intrathecal administration.